CD117 (c-kit) expression in human hepatocellular carcinoma.
Clin Oncol (R Coll Radiol)
; 19(3): 204-8, 2007 Apr.
Article
en En
| MEDLINE
| ID: mdl-17359908
ABSTRACT
AIMS:
Although various methods of treatment have been tried, treatment options for advanced hepatocellular carcinoma (HCC) remain limited. Expression of the platelet-derived growth factor has been shown in HCC, which may derive from hepatic stem cells that express the c-kit proto-oncogene. Because of the promising results of imatinib and the key role played by c-kit in gastrointestinal stromal tumours and other solid tumours, the aim of this study was to determine the prevalence of c-kit (CD117) overexpression in patients with HCC. MATERIALS ANDMETHODS:
A retrospective study of 258 archival specimens of subjects with histologically confirmed HCC was carried out. Expression of the c-kit proto-oncogene was evaluated by immunohistochemistry using rabbit anti-CD117 antibody A4502.RESULTS:
The overall percentage of positive immunohistochemical staining of HCCs was 2.3% (6/258).CONCLUSIONS:
Our results suggest that CD117 is not significantly overexpressed in HCC and there seems to be no role for the use of imatinib.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Proteínas Proto-Oncogénicas c-kit
/
Neoplasias Hepáticas
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2007
Tipo del documento:
Article